Engineered In Vitro Multi‐Cell Type Ventricle Model Generates Long‐Term Pulsatile Flow and Modulates Cardiac Output in Response to Cardioactive Drugs
Advanced Healthcare Materials · 2025
DOI: 10.1002/adhm.202403897 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, 2025. Verfasst von Christoph Kuckelkorn und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dental Materials and Biomaterials Research, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074, Aachen, Germany. Hauptthemen laut MEDLINE: Myocytes, Cardiac, Heart Ventricles, Tissue Engineering, Pulsatile Flow. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Cardiac in vitro models serve as promising platforms for physiological and pathological studies, drug testing, and regenerative medicine. This study hypothesizes that immobilizing cardiomyocytes derived from human induced pluripotent stem cells (iPSC‐CMs) on a biofunctionalized, hemispherical membrane can generate pulsatile flow through synchronized contractions, thus offering as an in vitro left ventricle model. To test this, a ventricle using a polydimethylsiloxane (PDMS) membrane coated with polydopamine and laminin 511 E8 fragments is engineered. Human iPSC‐CMs are cultured on these membranes, alone or in co‐culture with cardiac fibroblasts or endothelial cells, for 28 and 14 days, respectively, in a newly developed bioreactor. Flow measurements track beating and flow generation, while drug response, cardiac gene expression, and cell morphology are analyzed. The engineered ventricles maintain continuous beating and flow, achieving a theoretical cardiac output of up to 4 µL min −1 over 28 days, indicating stable cell adhesion and synchronized contraction. Cardiomyocytes respond to cardioactive drugs (carbachol, isoproterenol) and show expected changes in heart rate and cardiac output. In conclusion, the results demonstrate that the proposed engineered ventricle can serve as an in vitro left ventricle model by supporting cardiomyocyte culture and differentiation, generating long‐term stable flow, and responding physiologically to cardioactive drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dental Materials and Biomaterials Research, RWTH Aachen University Hospital, Pauwelsstrasse 30, 52074, Aachen, Germany.
- Center for Physiology and Pathophysiology, Institute for Neurophysiology, University and University Hospital of Cologne, Robert Koch Str. 39, 50931, Cologne, Germany.
- Center for Molecular Medicine Cologne (CMMC), 50931, Cologne, Germany.
- Marga-and-Walter-Boll-Laboratory for Cardiac Tissue Engineering, 50931, Cologne, Germany.
ORCID-Profile: Horst Fischer
Zitieren
APA
Kuckelkorn, C., Aksoy, E., Stojanovic, N., Oulahyane, L., Ritter, M., Pfannkuche, K., & Fischer, H. (2025). Engineered In Vitro Multi‐Cell Type Ventricle Model Generates Long‐Term Pulsatile Flow and Modulates Cardiac Output in Response to Cardioactive Drugs. Advanced Healthcare Materials. https://doi.org/10.1002/adhm.202403897
Vancouver
Kuckelkorn C, Aksoy E, Stojanovic N, Oulahyane L, Ritter M, Pfannkuche K, et al. Engineered In Vitro Multi‐Cell Type Ventricle Model Generates Long‐Term Pulsatile Flow and Modulates Cardiac Output in Response to Cardioactive Drugs. Advanced Healthcare Materials. 2025. doi:10.1002/adhm.202403897
BibTeX
@article{Kuckelkorn2025,
author = {Kuckelkorn, Christoph and Aksoy, Ebru and Stojanovic, Natalija and Oulahyane, Laila and Ritter, Mira and Pfannkuche, Kurt and Fischer, Horst},
title = {Engineered In Vitro Multi‐Cell Type Ventricle Model Generates Long‐Term Pulsatile Flow and Modulates Cardiac Output in Response to Cardioactive Drugs},
journal = {Advanced Healthcare Materials},
year = {2025},
doi = {10.1002/adhm.202403897}
}
EUVIMED